Patient-Derived Organoids (PDOs) are derived from adult stem cells from colorectal cancer patient biopsy tissue. When grown under controlled conditions to the scale and consistency necessary, they are an excellent cancer model on which to test potential new therapeutics and predict patient response in early-stage drug discovery. 

Molecular Devices’ technology enables the growth and expansion of PDOs. We currently have ten 3D Ready™ Colorectal Cancer Organoids (PDO)  lines available that cover a spectrum of genetic sub-types representing key oncogenic mutations. These organoids are cryopreserved, supplied from large scale batches.